Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Bioinformatics (Oxford, England)|October 3, 2021
FLINO: a new method for immunofluorescence bioimage normalizationJohn Graf, Sanghee Cho, Elizabeth McDonough, et al.
EMBO Reports|January 26, 2022
USP17 is required for peripheral trafficking of lysosomesJia Lin, Aidan P McCann, Naphannop Sereesongsaeng, et al.
Molecular Cancer Therapeutics|February 28, 2018
The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic BRAF Mutant Colorectal CancerNicholas Forsythe, Alaa Refaat, Arman Javadi, et al.
Scientific Reports|February 20, 2021
Modulating the unfolded protein response with ONC201 to impact on radiation response in prostate cancer cellsFrancesca Amoroso, Kimberley Glass, Reema Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2013
AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancerPhilip D Dunne, Darragh G McArt, Jaine K Blayney, et al.
Cell Reports|June 17, 2014
ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancerSandra Van Schaeybroeck, Murugan Kalimutho, Philip D Dunne, et al.
British Journal of Cancer|September 11, 2020
Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancerMichelle K Greene, Ting Chen, Eifion Robinson, et al.
Oncotarget|April 25, 2015
The prognostic value of the stem-like group in colorectal cancer using a panel of immunohistochemistry markersChee Wee Ong, Pei Yi Chong, Darragh G McArt, et al.
Cell Death & Disease|October 30, 2020
RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancerHajrah Khawaja, Andrew Campbell, Jamie Z Roberts, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2015
EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal CancerPhilip D Dunne, Sonali Dasgupta, Jaine K Blayney, et al.
Pageof 5